Tech Company Financing Transactions

Inflammatix Funding Round

Khosla Ventures, Think.Health and D1 Capital Partners joined a $57 million Series E capital raise for Inflammatix. The financing round was announced on 9/12/2024.

Transaction Overview

Company Name
Inflammatix
Announced On
9/12/2024
Transaction Type
Venture Equity
Amount
$57,000,000
Round
Series E
Investors

Khosla Ventures (Lead Investor)

Think.Health (Lead Investor)

D1 Capital Partners (James Rogers)

Iberis Capital

Northpond Ventures (Michael Rubin)

OSF Healthcare

Raw Ventures

Vesalius Biocapital

Proceeds Purpose
The company intends to use the funds for support regulatory filing and early commercialization its lead product, the TriVerity� Acute Infection and Sepsis Test (TriVerity).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
863 Mitten Rd. 104
Burlingame, CA 94010
USA
Phone
(650) 443-3030
Website
www.inflammatix.com
Email Address
[email protected]
Overview
Inflammatix is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. We are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.
Profile
Inflammatix LinkedIn Company Profile
Social Media
Inflammatix Company Twitter Account
Company News
Inflammatix News
Facebook
Inflammatix on Facebook
YouTube
Inflammatix on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Timothy Sweeney
  Timothy Sweeney LinkedIn Profile  Timothy Sweeney Twitter Account  Timothy Sweeney News  Timothy Sweeney on Facebook
Chief Medical Officer
Oliver Liesenfeld
  Oliver Liesenfeld LinkedIn Profile  Oliver Liesenfeld Twitter Account  Oliver Liesenfeld News  Oliver Liesenfeld on Facebook
Chief Technical Officer
Joao Fonseca
  Joao Fonseca LinkedIn Profile  Joao Fonseca Twitter Account  Joao Fonseca News  Joao Fonseca on Facebook
Co-Founder
Purvesh Khatri
  Purvesh Khatri LinkedIn Profile  Purvesh Khatri Twitter Account  Purvesh Khatri News  Purvesh Khatri on Facebook
Vice President
Ljubomir Buturovic
  Ljubomir Buturovic LinkedIn Profile  Ljubomir Buturovic Twitter Account  Ljubomir Buturovic News  Ljubomir Buturovic on Facebook
Vice President
Yudong He
  Yudong He LinkedIn Profile  Yudong He Twitter Account  Yudong He News  Yudong He on Facebook
Vice President
Pamela Lambert
  Pamela Lambert LinkedIn Profile  Pamela Lambert Twitter Account  Pamela Lambert News  Pamela Lambert on Facebook
VP - Bus. Development
Jonathan Romanowsky
  Jonathan Romanowsky LinkedIn Profile  Jonathan Romanowsky Twitter Account  Jonathan Romanowsky News  Jonathan Romanowsky on Facebook
VP - Engineering
Paul Fleming
  Paul Fleming LinkedIn Profile  Paul Fleming Twitter Account  Paul Fleming News  Paul Fleming on Facebook
VP - Finance
Howard Solovei
  Howard Solovei LinkedIn Profile  Howard Solovei Twitter Account  Howard Solovei News  Howard Solovei on Facebook
VP - Marketing
Nina Menezes
  Nina Menezes LinkedIn Profile  Nina Menezes Twitter Account  Nina Menezes News  Nina Menezes on Facebook
VP - Regulatory Affairs
Diana Lane
  Diana Lane LinkedIn Profile  Diana Lane Twitter Account  Diana Lane News  Diana Lane on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/12/2024: F2G venture capital transaction
Next: 9/12/2024: Push Cash venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.